A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 27 400 KRW 3.79% Market Closed
Market Cap: 1.3T KRW
Have any thoughts about
ABL Bio Inc?
Write Note

ABL Bio Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ABL Bio Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
Operating Income
-â‚©35.8B
CAGR 3-Years
16%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Operating Income
â‚©314B
CAGR 3-Years
-24%
CAGR 5-Years
0%
CAGR 10-Years
8%
SK Bioscience Co Ltd
KRX:302440
Operating Income
-â‚©12B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Operating Income
â‚©156.5B
CAGR 3-Years
14%
CAGR 5-Years
19%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Operating Income
â‚©109.6B
CAGR 3-Years
30%
CAGR 5-Years
52%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Operating Income
-â‚©5.7B
CAGR 3-Years
39%
CAGR 5-Years
11%
CAGR 10-Years
N/A
No Stocks Found

ABL Bio Inc
Glance View

Market Cap
1.3T KRW
Industry
Biotechnology

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

Intrinsic Value
8 401.38 KRW
Overvaluation 69%
Intrinsic Value
Price
A

See Also

What is ABL Bio Inc's Operating Income?
Operating Income
-35.8B KRW

Based on the financial report for Jun 30, 2024, ABL Bio Inc's Operating Income amounts to -35.8B KRW.

What is ABL Bio Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-21%

Over the last year, the Operating Income growth was 15%. The average annual Operating Income growth rates for ABL Bio Inc have been 16% over the past three years , -21% over the past five years .

Back to Top